Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30413379

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Dec
First author
van Ramshorst MS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Dec;19(12):1551-1554. doi: 10.1016/S1470-2045(18)30661-2.
    note
    Source null
    related pmid
    30413380
    relationship
    Comment in

Authors and identifiers

  1. name
    van Ramshorst MS
    type
    Author
  2. name
    van der Voort A
    type
    Author
  3. name
    van Werkhoven ED
    type
    Author
  4. name
    Mandjes IA
    type
    Author
  5. name
    Kemper I
    type
    Author
  6. name
    Dezentjé VO
    type
    Author
  7. name
    Oving IM
    type
    Author
  8. name
    Honkoop AH
    type
    Author
  9. name
    Tick LW
    type
    Author
  10. name
    van de Wouw AJ
    type
    Author
  11. name
    Mandigers CM
    type
    Author
  12. name
    van Warmerdam LJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    van Ramshorst MS
    type
    Author
  2. name
    van der Voort A
    type
    Author
  3. name
    van Werkhoven ED
    type
    Author
  4. name
    Mandjes IA
    type
    Author
  5. name
    Kemper I
    type
    Author
  6. name
    Dezentjé VO
    type
    Author
  7. name
    Oving IM
    type
    Author
  8. name
    Honkoop AH
    type
    Author
  9. name
    Tick LW
    type
    Author
  10. name
    van de Wouw AJ
    type
    Author
  11. name
    Mandigers CM
    type
    Author
  12. name
    van Warmerdam LJ
    type
    Author
bibliography ids
  1. nci-bib-5eed5c7739abddf7897cedae
book metadata
content sha256
04d38166b343e6ece13a79f5c356314ca5f06a98888a9f61b5739c3aa10c7203
document type
citation
dois
  1. 10.1016/S1470-2045(18)30570-9
electronic publication date
display
2018 Nov 6
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30413379
immutable id
pubmed:30413379@04d38166b343e6ece13a79f5c356314ca5f06a98888a9f61b5739c3aa10c7203
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
12
name
The Lancet. Oncology
nlm unique id
100957246
pages
1630-1640
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Dec;19(12):1551-1554. doi: 10.1016/S1470-2045(18)30661-2.
    note
    Source null
    related pmid
    30413380
    relationship
    Comment in
outcomes validated
false
pmid
30413379
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
ddf926e933e46ef4c99ea1fd46ccf17ac31567c1f35cc04ac0be3bb8b598f23f
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2018 Dec
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30413379/
title
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice